Archive | October, 2016

Biotech Meltdown: Financial Metrics Offer Few Clues For What is Next

Biotech Meltdown: Numbers Don’t Mean Much Until We See New Product Growth We are almost through the earnings season and despite good results most biotech stocks tanked again today.The reason you know well by now-expectations for earnings and top line growth have been taken down because price increases are not likely for 2017 . Another […]

Continue Reading 0

Biotech Bear Market Looking For Relief From Q3 Large Cap Growth…Update-3

Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson (MCK). All large caps are red except Alexion (ALXN) up 1.83%. Abbvie (ABBV) down 6% on revenue miss;Humira […]

Continue Reading 0

BIO Investor Forum 2016 #2:”Liquid Biopsy” Tests for Cancer…Update-1

CLIA Labs Offer Liquid Biopsy Tests for Cancer and Precision Medicine We attended presentations from two emerging companies developing molecular diagnostics platforms focused in cancer.Their mission is to develop cost-effective, non-invasive diagnostic assays and biomarkers directly from blood or urine eliminating  the need for tissue samples, the “liquid biopsy”.With DNA sequencing broadly available it is […]

Continue Reading 0

BIO Investor Forum 2016 #1: Translating Microbiome Research Into Treatments

Microbiomes: A New Paradigm for Drug Discovery? Focus: Drugs From Gut Bacteria You may have read a few articles about the impact of the microbiomes and their impact on diets, digestion and nutrition but now there is the potential of discovering new therapies from bacteria in your gut. We are not talking about faecal transplant therapy (FMT) […]

Continue Reading 0

BIO Investor Forum October 18-19, 2016… Preview

BIO Investor Forum 2016 We will be attending the BIO Investor Forum beginning Tuesday October 18 for two days. Last year the meeting was excellent for coverage of small cap biotech companies and important issues and trends in the life science industry. Over 100 companies will present in 2016. Here are some links to selected […]

Continue Reading 0

Biotechnology Bear Market: Trends to Watch for a 2016 Q4 Rally…Updates

Update-1… 10/14…2:30p EDT Ariad Pharmaceuticals (ARIA) Drops 8.25% to $12 on Senator Bernie Sanders Criticism of Drug  Pricing; Sanders was also on Bill Maher (HBO) XBI down 2.25% just below support of $60 Update-2… 10/15…Biotech Blues-Tough Week for Biotech and Healthcare IBB down 6.34%, XBI down 7.16%, XLV down 3.13% Nasdaq down 1.54% —- Bad […]

Continue Reading 0

Illumina (ILMN) Misses Revenue Forecast Causing Collateral Damage to Biotechs

Update-1 Biotechs Sinking Again …IBB down 2.48%, ILMN down another 2% Related sequencing stocks: FMI down 1.75%, PACB flat at $8.40 Illumina (ILMN) Shares Crash on Revenue Miss Illumina (ILMN) shares crashed 25% to $139, after a warning on third quarter sales . The global leader in DNA sequencing systems warned that revenues missed forecast and would […]

Continue Reading 0

Biotech Stocks Recovering from Last Week’s Free Fall: XBI…Update-2

Green Tape Today Shows Resilience– 10/10/16 ESMO Cancer Congress 4%+ Up movers: AGIO ARIA BLUE CLVS LGND PBYI TSRO etc. XBI up 2.39% More Bad Clinical News for Biotech:ALNY,CLVS The XBI lost 3.2% for the week to $64.15 taking a hit from Alnylam (ALNY) downdraft down 49% for the week. The IBB also took a […]

Continue Reading 0